vs
Side-by-side financial comparison of FRANKLIN STREET PROPERTIES CORP (FSP) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $23.0M, roughly 1.1× Intellia Therapeutics, Inc.). FRANKLIN STREET PROPERTIES CORP runs the higher net margin — -28.1% vs -416.2%, a 388.0% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -8.2%). FRANKLIN STREET PROPERTIES CORP produced more free cash flow last quarter ($-12.7M vs $-69.4M). Over the past eight quarters, FRANKLIN STREET PROPERTIES CORP's revenue compounded faster (-8.7% CAGR vs -10.8%).
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FSP vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0M | $23.0M |
| Net Profit | $-7.3M | $-95.8M |
| Gross Margin | 59.4% | — |
| Operating Margin | -27.9% | -428.9% |
| Net Margin | -28.1% | -416.2% |
| Revenue YoY | -8.2% | 78.8% |
| Net Profit YoY | 14.1% | 25.7% |
| EPS (diluted) | $-0.06 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0M | $23.0M | ||
| Q3 25 | $27.3M | $13.8M | ||
| Q2 25 | $26.7M | $14.2M | ||
| Q1 25 | $27.1M | $16.6M | ||
| Q4 24 | $28.4M | $12.9M | ||
| Q3 24 | $29.7M | $9.1M | ||
| Q2 24 | $30.8M | $7.0M | ||
| Q1 24 | $31.2M | $28.9M |
| Q4 25 | $-7.3M | $-95.8M | ||
| Q3 25 | $-8.3M | $-101.3M | ||
| Q2 25 | $-7.9M | $-101.3M | ||
| Q1 25 | $-21.4M | $-114.3M | ||
| Q4 24 | $-8.5M | $-128.9M | ||
| Q3 24 | $-15.6M | $-135.7M | ||
| Q2 24 | $-21.0M | $-147.0M | ||
| Q1 24 | $-7.6M | $-107.4M |
| Q4 25 | 59.4% | — | ||
| Q3 25 | 60.9% | — | ||
| Q2 25 | 59.9% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 61.0% | — | ||
| Q2 24 | 64.2% | — | ||
| Q1 24 | 64.7% | — |
| Q4 25 | -27.9% | -428.9% | ||
| Q3 25 | -30.5% | -808.9% | ||
| Q2 25 | -29.2% | -772.2% | ||
| Q1 25 | -78.9% | -726.6% | ||
| Q4 24 | -29.9% | -1059.9% | ||
| Q3 24 | -52.4% | -1589.0% | ||
| Q2 24 | -68.0% | -1998.6% | ||
| Q1 24 | -24.0% | -394.0% |
| Q4 25 | -28.1% | -416.2% | ||
| Q3 25 | -30.5% | -735.2% | ||
| Q2 25 | -29.5% | -710.8% | ||
| Q1 25 | -79.1% | -687.6% | ||
| Q4 24 | -30.0% | -1001.2% | ||
| Q3 24 | -52.6% | -1489.5% | ||
| Q2 24 | -68.2% | -2112.6% | ||
| Q1 24 | -24.2% | -371.3% |
| Q4 25 | $-0.06 | $-0.81 | ||
| Q3 25 | $-0.08 | $-0.92 | ||
| Q2 25 | $-0.08 | $-0.98 | ||
| Q1 25 | $-0.21 | $-1.10 | ||
| Q4 24 | $-0.09 | $-1.27 | ||
| Q3 24 | $-0.15 | $-1.34 | ||
| Q2 24 | $-0.20 | $-1.52 | ||
| Q1 24 | $-0.07 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $30.6M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $607.0M | $671.4M |
| Total Assets | $892.9M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.6M | $449.9M | ||
| Q3 25 | $31.4M | $511.0M | ||
| Q2 25 | $29.4M | $459.7M | ||
| Q1 25 | $30.2M | $503.7M | ||
| Q4 24 | $41.1M | $601.5M | ||
| Q3 24 | $40.9M | $658.1M | ||
| Q2 24 | $30.2M | $691.1M | ||
| Q1 24 | $34.2M | $791.3M |
| Q4 25 | $607.0M | $671.4M | ||
| Q3 25 | $615.3M | $748.4M | ||
| Q2 25 | $624.7M | $715.3M | ||
| Q1 25 | $633.4M | $779.9M | ||
| Q4 24 | $655.9M | $872.0M | ||
| Q3 24 | $665.4M | $962.6M | ||
| Q2 24 | $682.1M | $971.1M | ||
| Q1 24 | $703.9M | $1.0B |
| Q4 25 | $892.9M | $842.1M | ||
| Q3 25 | $901.0M | $925.3M | ||
| Q2 25 | $903.2M | $898.9M | ||
| Q1 25 | $916.4M | $986.2M | ||
| Q4 24 | $946.9M | $1.2B | ||
| Q3 24 | $981.5M | $1.2B | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $1.0B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.8M | $-69.3M |
| Free Cash FlowOCF − Capex | $-12.7M | $-69.4M |
| FCF MarginFCF / Revenue | -48.6% | -301.6% |
| Capex IntensityCapex / Revenue | 63.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-25.3M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.8M | $-69.3M | ||
| Q3 25 | $8.3M | $-76.9M | ||
| Q2 25 | $-2.9M | $-99.6M | ||
| Q1 25 | $-5.5M | $-148.9M | ||
| Q4 24 | $9.0M | $-85.2M | ||
| Q3 24 | $14.5M | $-84.8M | ||
| Q2 24 | $-648.0K | $-58.2M | ||
| Q1 24 | $-7.1M | $-120.7M |
| Q4 25 | $-12.7M | $-69.4M | ||
| Q3 25 | $3.0M | $-76.9M | ||
| Q2 25 | $-5.7M | $-99.9M | ||
| Q1 25 | $-9.9M | $-149.7M | ||
| Q4 24 | $-16.2M | $-86.2M | ||
| Q3 24 | $8.6M | $-86.1M | ||
| Q2 24 | $-5.1M | $-59.2M | ||
| Q1 24 | $-15.8M | $-123.2M |
| Q4 25 | -48.6% | -301.6% | ||
| Q3 25 | 11.0% | -558.2% | ||
| Q2 25 | -21.5% | -701.0% | ||
| Q1 25 | -36.7% | -900.1% | ||
| Q4 24 | -57.2% | -669.4% | ||
| Q3 24 | 29.1% | -945.2% | ||
| Q2 24 | -16.7% | -850.9% | ||
| Q1 24 | -50.8% | -425.7% |
| Q4 25 | 63.0% | 0.5% | ||
| Q3 25 | 19.4% | 0.2% | ||
| Q2 25 | 10.7% | 1.7% | ||
| Q1 25 | 16.4% | 4.4% | ||
| Q4 24 | 88.9% | 7.6% | ||
| Q3 24 | 19.6% | 14.0% | ||
| Q2 24 | 14.6% | 14.5% | ||
| Q1 24 | 28.1% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSP
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
